Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure-response analysis.

Tsamandouras N, Duvvuri S, Riley S.

J Pharmacokinet Pharmacodyn. 2019 Dec;46(6):605-616. doi: 10.1007/s10928-019-09661-4. Epub 2019 Oct 29.

PMID:
31664592
2.

Physiologically Relevant, Humanized Intestinal Systems to Study Metabolism and Transport of Small Molecule Therapeutics.

Sawant-Basak A, Rodrigues AD, Lech M, Doyonnas R, Kasaian M, Prasad B, Tsamandouras N.

Drug Metab Dispos. 2018 Nov;46(11):1581-1587. doi: 10.1124/dmd.118.082784. Epub 2018 Aug 20. Review.

PMID:
30126862
3.

Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies.

Edington CD, Chen WLK, Geishecker E, Kassis T, Soenksen LR, Bhushan BM, Freake D, Kirschner J, Maass C, Tsamandouras N, Valdez J, Cook CD, Parent T, Snyder S, Yu J, Suter E, Shockley M, Velazquez J, Velazquez JJ, Stockdale L, Papps JP, Lee I, Vann N, Gamboa M, LaBarge ME, Zhong Z, Wang X, Boyer LA, Lauffenburger DA, Carrier RL, Communal C, Tannenbaum SR, Stokes CL, Hughes DJ, Rohatgi G, Trumper DL, Cirit M, Griffith LG.

Sci Rep. 2018 Mar 14;8(1):4530. doi: 10.1038/s41598-018-22749-0.

4.

Integrated Gut and Liver Microphysiological Systems for Quantitative In Vitro Pharmacokinetic Studies.

Tsamandouras N, Chen WLK, Edington CD, Stokes CL, Griffith LG, Cirit M.

AAPS J. 2017 Sep;19(5):1499-1512. doi: 10.1208/s12248-017-0122-4. Epub 2017 Jul 27.

5.

Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population.

Tsamandouras N, Guo Y, Wendling T, Hall S, Galetin A, Aarons L.

Pharmacogenet Genomics. 2017 Jan;27(1):27-38.

PMID:
27787353
6.

Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System.

Tsamandouras N, Kostrzewski T, Stokes CL, Griffith LG, Hughes DJ, Cirit M.

J Pharmacol Exp Ther. 2017 Jan;360(1):95-105. Epub 2016 Oct 19.

7.

Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction.

Satia I, Tsamandouras N, Holt K, Badri H, Woodhead M, Ogungbenro K, Felton TW, O'Byrne PM, Fowler SJ, Smith JA.

J Allergy Clin Immunol. 2017 Mar;139(3):771-779.e10. doi: 10.1016/j.jaci.2016.04.045. Epub 2016 Jun 15.

8.

Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data.

Wendling T, Tsamandouras N, Dumitras S, Pigeolet E, Ogungbenro K, Aarons L.

AAPS J. 2016 Jan;18(1):196-209. doi: 10.1208/s12248-015-9840-7. Epub 2015 Nov 4.

9.

Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations.

Tsamandouras N, Wendling T, Rostami-Hodjegan A, Galetin A, Aarons L.

J Pharmacokinet Pharmacodyn. 2015 Aug;42(4):349-73. doi: 10.1007/s10928-015-9418-0. Epub 2015 May 26.

PMID:
26006250
10.

Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach.

Tsamandouras N, Dickinson G, Guo Y, Hall S, Rostami-Hodjegan A, Galetin A, Aarons L.

Pharm Res. 2015 Jun;32(6):1864-83. doi: 10.1007/s11095-014-1581-2. Epub 2014 Dec 2.

PMID:
25446771
11.

Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.

Gertz M, Tsamandouras N, Säll C, Houston JB, Galetin A.

Pharm Res. 2014 Sep;31(9):2367-82. doi: 10.1007/s11095-014-1333-3. Epub 2014 Mar 13.

PMID:
24623479
12.

Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach.

Tsamandouras N, Dickinson G, Guo Y, Hall S, Rostami-Hodjegan A, Galetin A, Aarons L.

Clin Pharmacol Ther. 2014 Jul;96(1):90-100. doi: 10.1038/clpt.2014.55. Epub 2014 Mar 5.

PMID:
24598718
13.

Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.

Tsamandouras N, Rostami-Hodjegan A, Aarons L.

Br J Clin Pharmacol. 2015 Jan;79(1):48-55. doi: 10.1111/bcp.12234. Review.

Supplemental Content

Loading ...
Support Center